About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients with type 2 diabetes in this study. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain obesity-associated cancers.
About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients with type 2 diabetes in this study. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain obesity-associated cancers.
Corresponding Authors: To contact the corresponding authors, email Nathan A. Berger, M.D. (nab@case.edu) and Rong Xu, Ph.D. (rxx@case.edu).
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamanetworkopen.2024.21305)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open
Discover more from Science
Subscribe to get the latest posts sent to your email.
